Earnest Partners LLC trimmed its holdings in Agilent Technologies Inc (NYSE:A) by 0.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 375,174 shares of the medical research company’s stock after selling 3,006 shares during the period. Earnest Partners LLC owned 0.12% of Agilent Technologies worth $25,125,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Dupont Capital Management Corp acquired a new position in shares of Agilent Technologies in the 3rd quarter valued at about $101,000. Front Row Advisors LLC acquired a new position in shares of Agilent Technologies in the 4th quarter valued at about $106,000. AMG National Trust Bank acquired a new position in shares of Agilent Technologies in the 4th quarter valued at about $201,000. Premia Global Advisors LLC acquired a new position in shares of Agilent Technologies in the 4th quarter valued at about $204,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of Agilent Technologies in the 3rd quarter valued at about $213,000.
Shares of Agilent Technologies Inc (A) opened at $70.68 on Wednesday. The company has a market capitalization of $22,819.34, a PE ratio of 119.80, a P/E/G ratio of 2.36 and a beta of 1.30. The company has a current ratio of 3.23, a quick ratio of 2.78 and a debt-to-equity ratio of 0.40. Agilent Technologies Inc has a twelve month low of $51.96 and a twelve month high of $75.00.
In other Agilent Technologies news, insider Mark Doak sold 15,567 shares of Agilent Technologies stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $68.00, for a total transaction of $1,058,556.00. Following the sale, the insider now directly owns 71,104 shares in the company, valued at approximately $4,835,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael R. Mcmullen sold 43,703 shares of Agilent Technologies stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $70.00, for a total value of $3,059,210.00. Following the sale, the chief executive officer now owns 302,837 shares in the company, valued at $21,198,590. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,970 shares of company stock worth $7,340,641.
Several research firms have recently weighed in on A. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Robert W. Baird reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Agilent Technologies in a research note on Friday, November 24th. Finally, Barclays lifted their price objective on Agilent Technologies from $67.00 to $71.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $71.27.
COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/agilent-technologies-inc-a-shares-sold-by-earnest-partners-llc.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.